CD4 and neoplasm: In conclusion, we demonstrate that Uro A effectively reduces primary tumor burden in a T cell–dependent manner, attenuates immunosuppressive M2-like TAMs, and significantly increases the infiltration of CD4+ and CD8+ T cells with a memory-like phenotype in the PDAC TME.